tirzepatide surpass-5 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Post Hoc Analysis of SURPASS-1

Bausch Health US, LLC [Bridgewater, NJ, USA]), which was the first approved rescue medication for seizure clusters [27, 28]

Eli Lilly has not yet announced plans for domestic partnerships to market the drug, whose global revenue surged 60% on-year to $3.53 billion in the December quarter

(2) GIP and GLP-1 target overlapping but distinct hypothalamic circuitsGIP may augment satiety through the infundibular nucleus in ways complementary to GLP-1's arcuate nucleus effects

SmPC last updated 26 February 2026)Tier 1 primary [2]EMA CHMP meeting highlights (8-11 December 2025): positive opinion to extend Mounjaro (tirzepatide) to type-2 diabetes in adolescents and children aged 10 and overTier 1 primary [3]SURPASS-2: Frias JP et al., Tirzepatide versus semaglutide once weekly in patients with type-2 diabetes (NEJM, 2021

Oral Tirzepatide Weight Loss Program From: $399.00 every 4 weeks Quick Online Medical Consultations Unlimited Access to Expert Medical Guidance Monthly Prescription Review for Optimal Results Payment auto-refund if monthly assessment is not filled Premium Customer Support Throughout Treatment How to Get Started: Fill Out Your Health Questionnaire Begin by completing a secure, easy-to-follow online health assessment